AeRang Kim

AeRang Kim


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
PBPeter Matthew De Blank
Peter Matthew De Blank
AGAndrea Gross
Andrea Gross
SASrivandana Akshintala
Srivandana Akshintala
JBJaishri O Blakeley
Jaishri O Blakeley
GBGideon Bollag
Gideon Bollag
MFMichael J Fisher
Michael J Fisher
The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1 (NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase kinase inhibitors (MEKi) block downstream targets of RAS. The recent regulatory approvals of the MEKi selumetinib for inoperable symptomatic plexiform neurofibromas in children with NF1 have made it the first medical therapy approved for this indication in the United States, the European Union, and elsewhere. Several recently published and ongoing clinical trials have demonstrated that MEKi may have potential benefits for a variety of other NF1 manifestations, and there is broad interest in the field regarding the appropriate clinical use of these agents. In this review, we present the current evidence regarding the use of existing MEKi for a variety of NF1-related manifestations, including tumor (neurofibromas, malignant peripheral nerve sheath tumors, low-grade glioma, and juvenile myelomonocytic leukemia) and non-tumor (bone, pain, and neurocognitive) manifestations. We discuss the potential utility of MEKi in related genetic conditions characterized by overactivation of the RAS pathway (RASopathies). In addition, we review practical treatment considerations for the use of MEKi as well as provide consensus recommendations regarding their clinical use from a panel of experts.

1 January 2017 in Sarcoma
Verified
Journal Article
Open access
PDF file
AKAeRang Kim
AeRang Kim
DSDouglas R. Stewart
Douglas R. Stewart
KRKarlyne M. Reilly
Karlyne M. Reilly
DVDavid Viskochil
David Viskochil
MMMarkku M. Miettinen
Markku M. Miettinen
BWBrigitte C. Widemann
Brigitte C. Widemann
Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of mortality in patients with neurofibromatosis type 1. In 2002, an MPNST consensus statement reviewed the current knowledge and provided guidance for the diagnosis and management of MPNST. Although the improvement in clinical outcome has not changed, substantial progress has been made in understanding the natural history and biology of MPNST through imaging and genomic advances since 2002. Genetically engineered mouse models that develop MPNST spontaneously have greatly facilitated preclinical evaluation of novel drugs for translation into clinical trials led by consortia efforts. Continued work in identifying alterations that contribute to the transformation, progression, and metastasis of MPNST coupled with longitudinal follow-up, biobanking, and data sharing is needed to develop prognostic biomarkers and effective prevention and therapeutic strategies for MPNST.

28 April 2023 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
AGAndrea Gross
Andrea Gross
EDEva Dombi
Eva Dombi
PWPamela L Wolters
Pamela L Wolters
ABAndrea Baldwin
Andrea Baldwin
ADAnne Dufek
Anne Dufek
BWBrigitte C Widemann
Brigitte C Widemann
Background: Selumetinib shrank inoperable symptomatic plexiform neurofibromas (PN) in children with neurofibromatosis type 1 (NF1) and provided clinical benefit for many in our previously published phase 1/2 clinical trials (SPRINT, NCT01362803). At the data cutoff (DCO) of the prior publications, 65% of participants were still receiving treatment. This report presents up to 5 years of additional safety and efficacy data from these studies. Methods: This manuscript includes data from the phase 1 and phase 2, stratum 1 study which included participants with clinically significant PN-related morbidity. Participants received continuous selumetinib dosing (1 cycle = 28 days). Safety and efficacy data through February 27, 2021 are included. PN response assessed by volumetric magnetic resonance imaging analysis: Confirmed partial response (cPR) ≥20% decrease from baseline on 2 consecutive evaluations. Phase 2 participants completed patient-reported outcome measures assessing tumor pain intensity (Numeric Rating Scale-11) and interference of pain in daily life (pain interference index). Results: For the 74 children (median age 10.3 years; range 3–18.5) enrolled, overall cPR rate was 70% (52/74); median duration of treatment was 57.5 cycles (range 1–100). Responses were generally sustained with 59% (44) lasting ≥ 12 cycles. Tumor pain intensity (n = 19, P = .015) and pain interference (n = 18, P = .0059) showed durable improvement from baseline to 48 cycles. No new safety signals were identified; however, some developed known selumetinib-related adverse events (AEs) for the first time after several years of treatment. Conclusions: With up to 5 years of additional selumetinib treatment, most children with NF1-related PN had durable tumor shrinkage and sustained improvement in pain beyond that previously reported at 1 year. No new safety signals were identified; however, ongoing monitoring for known selumetinib-related AEs is needed while treatment continues.

27 April 2015 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
AKAeRang Kim
AeRang Kim
BWBrigitte C. Widemann
Brigitte C. Widemann
MKMark Krailo
Mark Krailo
NJNalini Jayaprakash
Nalini Jayaprakash
EFElizabeth Fox
Elizabeth Fox
SBSusan M. Blaney
Susan M. Blaney

17 March 2015 in Current Treatment Options in Oncology
Verified
Journal Article
Closed access
PDF file
DBDiana Bradford
Diana Bradford
AKAeRang Kim
AeRang Kim

1 September 2015 in International Journal of Pediatric Otorhinolaryngology
Verified
Journal Article
Closed access
BRBrian K. Reilly
Brian K. Reilly
AKAeRang Kim
AeRang Kim
MPMaria T. Peña
Maria T. Peña
TDTiffany A. Dong
Tiffany A. Dong
CRChristopher Rossi
Christopher Rossi
SCSukgi S. Choi
Sukgi S. Choi